Calidi Biotherapeutics Net Income
| CLDI Stock | 0.78 0.02 2.63% |
As of the 15th of February 2026, Calidi Biotherapeutics shows the Standard Deviation of 3.47, mean deviation of 2.57, and Risk Adjusted Performance of (0.22). Calidi Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Calidi Biotherapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Calidi Biotherapeutics' valuation are provided below:Calidi Biotherapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value - what Calidi Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Calidi Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Calidi Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Calidi Biotherapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Calidi Biotherapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Calidi Biotherapeutics or generate 0.0% return on investment in Calidi Biotherapeutics over 90 days. Calidi Biotherapeutics is related to or competes with Clearmind Medicine, Can Fite, Kazia Therapeutics, Silo Pharma, CNS Pharmaceuticals, 60 Degrees, and Xenetic Biosciences. More
Calidi Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Calidi Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Calidi Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.30) | |||
| Maximum Drawdown | 18.21 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 4.48 |
Calidi Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Calidi Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Calidi Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use Calidi Biotherapeutics historical prices to predict the future Calidi Biotherapeutics' volatility.| Risk Adjusted Performance | (0.22) | |||
| Jensen Alpha | (1.00) | |||
| Total Risk Alpha | (1.26) | |||
| Treynor Ratio | 25.28 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Calidi Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Calidi Biotherapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.22) | |||
| Market Risk Adjusted Performance | 25.29 | |||
| Mean Deviation | 2.57 | |||
| Coefficient Of Variation | (351.23) | |||
| Standard Deviation | 3.47 | |||
| Variance | 12.05 | |||
| Information Ratio | (0.30) | |||
| Jensen Alpha | (1.00) | |||
| Total Risk Alpha | (1.26) | |||
| Treynor Ratio | 25.28 | |||
| Maximum Drawdown | 18.21 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 4.48 | |||
| Skewness | (0.59) | |||
| Kurtosis | 1.18 |
Calidi Biotherapeutics Backtested Returns
Calidi Biotherapeutics secures Sharpe Ratio (or Efficiency) of -0.28, which signifies that the company had a -0.28 % return per unit of risk over the last 3 months. Calidi Biotherapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Calidi Biotherapeutics' Standard Deviation of 3.47, mean deviation of 2.57, and Risk Adjusted Performance of (0.22) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.0395, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Calidi Biotherapeutics are expected to decrease at a much lower rate. During the bear market, Calidi Biotherapeutics is likely to outperform the market. At this point, Calidi Biotherapeutics has a negative expected return of -0.99%. Please make sure to confirm Calidi Biotherapeutics' treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Calidi Biotherapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.68 |
Good predictability
Calidi Biotherapeutics has good predictability. Overlapping area represents the amount of predictability between Calidi Biotherapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Calidi Biotherapeutics price movement. The serial correlation of 0.68 indicates that around 68.0% of current Calidi Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.68 | |
| Spearman Rank Test | 0.68 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Calidi Biotherapeutics reported net income of (22.21 Million). This is 106.51% lower than that of the Biotechnology sector and 131.71% lower than that of the Health Care industry. The net income for all United States stocks is 103.89% higher than that of the company.
Calidi Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calidi Biotherapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Calidi Biotherapeutics could also be used in its relative valuation, which is a method of valuing Calidi Biotherapeutics by comparing valuation metrics of similar companies.Calidi Biotherapeutics is currently under evaluation in net income category among its peers.
Calidi Fundamentals
| Return On Asset | -1.2 | ||||
| Current Valuation | (1.46 M) | ||||
| Shares Outstanding | 7.17 M | ||||
| Shares Owned By Insiders | 23.20 % | ||||
| Shares Owned By Institutions | 5.30 % | ||||
| Number Of Shares Shorted | 259.45 K | ||||
| Price To Book | 0.81 X | ||||
| Price To Sales | 50.83 X | ||||
| Gross Profit | 31 K | ||||
| EBITDA | (19.73 M) | ||||
| Net Income | (22.21 M) | ||||
| Total Debt | 7.04 M | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (19.69 M) | ||||
| Short Ratio | 3.24 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Target Price | 120.0 | ||||
| Number Of Employees | 28 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 5.61 M | ||||
| Total Asset | 14.18 M | ||||
| Retained Earnings | (121.72 M) | ||||
| Working Capital | 731 K | ||||
| Net Asset | 14.18 M |
About Calidi Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calidi Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calidi Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calidi Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value - what Calidi Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.